<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938011</url>
  </required_header>
  <id_info>
    <org_study_id>SZ-2021-0616</org_study_id>
    <nct_id>NCT04938011</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Study of Prolonging the Time of Progesterone Supplementation to Improve the Pregnancy Outcome of Single Day 6 Blastocyst Transfer of Freeze-thaw Cycle</brief_title>
  <official_title>A Randomized Controlled Study of Prolonging the Time of Progesterone Supplementation to Improve the Pregnancy Outcome of Single Day 6 Blastocyst Transfer of Freeze-thaw Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, randomized controlled study. Patients with single&#xD;
      blastocyst transfer in the freeze-thaw cycle, aged from 20 to 38 years, with less than three&#xD;
      transfers, and with HRT-cycle single D6 blastocyst transfer in the current cycle were&#xD;
      enrolled as the study participants. They were randomized into two groups using an Excel&#xD;
      table, and the efficacy was evaluated in a blinded manner by a third party who was unaware of&#xD;
      the grouping; the data summary phase was performed by blinded statistical analysis with&#xD;
      triple separation of the investigator, operator, and statistician.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Embryo implantation rate</measure>
    <time_frame>30 days after embryo transplantation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Progesterone + 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the transfer of day 6 blastocyst on the 7th day of progesterone supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone + 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the transfer of day 6 blastocysts on the 6th day of progesterone supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>the transfer of day 6 blastocyst on the 6th day of progesterone supplementation</description>
    <arm_group_label>Progesterone + 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>the transfer of day 6 blastocyst on the 7th day of progesterone supplementation</description>
    <arm_group_label>Progesterone + 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 20 to 38 years.&#xD;
&#xD;
          2. Less than three transfers.&#xD;
&#xD;
          3. Undergoing HRT freeze-thaw cycle single blastocyst transfer in the current cycle.&#xD;
&#xD;
          4. Having consented to participate in this study and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chromosomal abnormality in either the patient or their partner&#xD;
&#xD;
          2. Contraindications to hormone replacement therapy.&#xD;
&#xD;
          3. Patients with intramural myoma affecting the morphology of the uterine cavity, severe&#xD;
             adenomyosis, endometriosis, congenital uterine anomalies, endometrial tuberculosis,&#xD;
             intrauterine adhesion and other diseases significantly affecting embryonic&#xD;
             implantation.&#xD;
&#xD;
          4. Currently participating in another clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yue Jiang, PhD</last_name>
    <phone>025-83106666</phone>
    <email>jiangyue85@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 19, 2021</study_first_submitted>
  <study_first_submitted_qc>June 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 19, 2021</last_update_submitted>
  <last_update_submitted_qc>June 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University</investigator_affiliation>
    <investigator_full_name>Li-jun Ding</investigator_full_name>
    <investigator_title>Reproductive Medicine Center of The Affiliated Drum Tower Hospital of Nanjing University Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

